Cerivastatin (Vietnamese Wikipedia)

Analysis of information sources in references of the Wikipedia article "Cerivastatin" in Vietnamese language version.

refsWebsite

Global rank Vietnamese rank

4^th place

7^th place

2^nd place

274^th place

484^th place

low place

6,663^rd place

5,799^th place

195^th place

120^th place

4,294^th place

9,122^nd place

222^nd place

aspetjournals.org

[6], Boberg M, Angerbauer R, Fey P, Kanhai WK, Karl W, Kern A, Ploschke J, Radtke M (1996). “Metabolism of cerivastatin by human liver microsomes in vitro”. Drug Metabolism and Dispersion, 25 (3): 321-331
[7], 15. Boberg M, Angerbauer R, Fey P, Kanhai WK, Karl W, Kern A, Ploschke J, Radtke M (1996). “Metabolism of cerivastatin by human liver microsomes in vitro”. Drug Metabolism and Dispersion, 25 (3): 321-331

Furberg CD, Pitt B (2001). “Withdrawal of cerivastatin from the world market”. Curr Control Trials Cardiovasc Med. 2 (5): 205–207. doi:10.1186/cvm-2-5-205. PMC 59524. PMID 11806796.
Psaty BM, Furberg CD, Ray WA, Weiss NS (2004). “Potential for conflict of interest in the evaluation of suspected adverse drug reactions: use of cerivastatin and risk of rhabdomyolysis”. JAMA. 292 (21): 2622–31. doi:10.1001/jama.292.21.2622. PMID 15572720.
Zeitlinger M, Müller M (2003). “[Clinico-pharmacologic explanation models of cerivastatin associated rhabdomyolysis]”. Wien Med Wochenschr (bằng tiếng Đức). 153 (11–12): 250–4. doi:10.1046/j.1563-258X.2003.03029.x. PMID 12879633.

[3], 10. Endo A (1992). “The discovery and development of HMG-CoA reductase inhibitors”. Journal of Lipid Research, 33: 1569-1582
[5], Miettinen TA (1982). “Diurnal variation of cholesterol precursors squalene and methyl sterols in human plasma lipoproteins”. The Journal of Lipid Research, 23: 466-473

Furberg CD, Pitt B (2001). “Withdrawal of cerivastatin from the world market”. Curr Control Trials Cardiovasc Med. 2 (5): 205–207. doi:10.1186/cvm-2-5-205. PMC 59524. PMID 11806796.
Psaty BM, Furberg CD, Ray WA, Weiss NS (2004). “Potential for conflict of interest in the evaluation of suspected adverse drug reactions: use of cerivastatin and risk of rhabdomyolysis”. JAMA. 292 (21): 2622–31. doi:10.1001/jama.292.21.2622. PMID 15572720.
Zeitlinger M, Müller M (2003). “[Clinico-pharmacologic explanation models of cerivastatin associated rhabdomyolysis]”. Wien Med Wochenschr (bằng tiếng Đức). 153 (11–12): 250–4. doi:10.1046/j.1563-258X.2003.03029.x. PMID 12879633.
Saito M, Hirata-Koizumi M, Miyake S, Hasegawa R (2005). “[Withdrawal of cerivastatin revealed a flaw of post-marketing surveillance system in the United States]”. Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku (bằng tiếng Nhật) (123): 41–5. PMID 16541751.

Furberg CD, Pitt B (2001). “Withdrawal of cerivastatin from the world market”. Curr Control Trials Cardiovasc Med. 2 (5): 205–207. doi:10.1186/cvm-2-5-205. PMC 59524. PMID 11806796.
[do:10.1001/jama.292.21.2622. PMID 15572720], Psaty BM, Furberg CD, Ray WA, Weiss NS (2004). "Potential for conflict of interest in the evaluation of suspected adverse drug reactions: use of cerivastatin and risk of rhabdomyolysis". JAMA. 292 (21): 2622–31
[doi:10.1001/jama.292.21.2622. PMID 15572720.], Psaty BM, Furberg CD, Ray WA, Weiss NS (2004). "Potential for conflict of interest in the evaluation of suspected adverse drug reactions: use of cerivastatin and risk of rhabdomyolysis". JAMA. 292 (21): 2622–31

[1], 7.Mück W. 2000. Clinical Pharmacokinetics of Cerivastatin. Clinical Pharmacokinetics 39(2):99-116
[4], 11. Laufs U, Custodis F, Böhm M (2006). “HMG-CoA Reductase Inhibitors in Chronic Heart Failure”. Drugs, 66: 145

[2], 8. Kuhlmann J, Mück W, Bischoff H, von Keutz H, Llewellyn M (1998). “Cerivastatin (BAY w 6228): A Novel HMG-CoA Reductase Inhibitor”. Cardiovascular Drug Reviews, 16 (3): 236-263